Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan.
Value Health. 2009 Nov-Dec; 12 Suppl 3:S62-5.VH

Abstract

AIM

The purpose of this study is to evaluate the cost-effectiveness of oseltamivir for influenza in Japan considering the complications and the emergence of oseltamivir-resistant virus.

METHODS

Study design is a cost-effectiveness analysis in decision analytic modeling based on previously published evidence. Outcome measures included costs and quality-adjusted life year (QALY).

RESULTS AND CONCLUSION

In the base-case analysis, the incremental cost-effectiveness ratio (ICER) of oseltamivir during influenza and complications was JPY398,571 ($3320) per QALY without productivity loss, which implied oseltamivir is evidently cost-effective. Furthermore, considering the productivity loss, the ICER for oseltamivir turned to be negative, which means simply dominant. When the prevalence was in the low range of 10% to 38%, oseltamivir became less cost-effective than conventional treatment. Regarding potential emergence of the drug-resistant virus, we found the dominance of oseltamivir will vanish if the emerging rate becomes larger than 27%. The two-way sensitivity analysis also suggested that if the resistant virus rate becomes less and the prevalence higher, then oseltamivir becomes more advantageous. The analysis for uncertainty, using cost-effectiveness acceptability curve by Monte Carlo simulation, resulted in the estimate of about 80% chance that oseltamivir could be cost-effective at the willingness-to-pay level of JPY6,000,000 ($50,000), which is commonly accepted as an affordable threshold.

Authors+Show Affiliations

Division of Medical Statistics, Graduate School of Medicine, Kobe University, Kobe, Japan. nagase@med.kobe-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20586984

Citation

Nagase, Hiroko, et al. "Cost-effectiveness Analysis of Oseltamivir for Influenza Treatment Considering the Virus Emerging Resistant to the Drug in Japan." Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 12 Suppl 3, 2009, pp. S62-5.
Nagase H, Moriwaki K, Kamae M, et al. Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan. Value Health. 2009;12 Suppl 3:S62-5.
Nagase, H., Moriwaki, K., Kamae, M., Yanagisawa, S., & Kamae, I. (2009). Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan. Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 12 Suppl 3, S62-5. https://doi.org/10.1111/j.1524-4733.2009.00629.x
Nagase H, et al. Cost-effectiveness Analysis of Oseltamivir for Influenza Treatment Considering the Virus Emerging Resistant to the Drug in Japan. Value Health. 2009;12 Suppl 3:S62-5. PubMed PMID: 20586984.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan. AU - Nagase,Hiroko, AU - Moriwaki,Kensuke, AU - Kamae,Maki, AU - Yanagisawa,Shinichiro, AU - Kamae,Isao, PY - 2010/7/1/entrez PY - 2010/7/10/pubmed PY - 2010/8/11/medline SP - S62 EP - 5 JF - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research JO - Value Health VL - 12 Suppl 3 N2 - AIM: The purpose of this study is to evaluate the cost-effectiveness of oseltamivir for influenza in Japan considering the complications and the emergence of oseltamivir-resistant virus. METHODS: Study design is a cost-effectiveness analysis in decision analytic modeling based on previously published evidence. Outcome measures included costs and quality-adjusted life year (QALY). RESULTS AND CONCLUSION: In the base-case analysis, the incremental cost-effectiveness ratio (ICER) of oseltamivir during influenza and complications was JPY398,571 ($3320) per QALY without productivity loss, which implied oseltamivir is evidently cost-effective. Furthermore, considering the productivity loss, the ICER for oseltamivir turned to be negative, which means simply dominant. When the prevalence was in the low range of 10% to 38%, oseltamivir became less cost-effective than conventional treatment. Regarding potential emergence of the drug-resistant virus, we found the dominance of oseltamivir will vanish if the emerging rate becomes larger than 27%. The two-way sensitivity analysis also suggested that if the resistant virus rate becomes less and the prevalence higher, then oseltamivir becomes more advantageous. The analysis for uncertainty, using cost-effectiveness acceptability curve by Monte Carlo simulation, resulted in the estimate of about 80% chance that oseltamivir could be cost-effective at the willingness-to-pay level of JPY6,000,000 ($50,000), which is commonly accepted as an affordable threshold. SN - 1524-4733 UR - https://www.unboundmedicine.com/medline/citation/20586984/Cost_effectiveness_analysis_of_oseltamivir_for_influenza_treatment_considering_the_virus_emerging_resistant_to_the_drug_in_Japan_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1098-3015(10)60342-7 DB - PRIME DP - Unbound Medicine ER -